Madrigal Pharmaceuticals, Inc. (MDGL)
NASDAQ: MDGL · Real-Time Price · USD
400.43
+4.11 (1.04%)
At close: Nov 4, 2026, 4:00 PM EST
395.01
-5.42 (-1.35%)
Pre-market: Nov 5, 2026, 7:47 AM EST
Madrigal Pharmaceuticals Revenue
Madrigal Pharmaceuticals had revenue of $431.27M in the quarter ending September 30, 2026, with 50.13% growth. This brings the company's total for the last twelve months to $1.43B, up 92.80% year-over-year. In the year 2025, Madrigal Pharmaceuticals had annual revenue of $958.40M with 432.05% growth. That makes Madrigal Pharmaceuticals the 6,179th largest company in the world by revenue and 1,547th in the United States.
Revenue (ttm)
$1.43B
Revenue Growth
+92.80%
P/S Ratio
6.51
Revenue / Employee
$1,560,590
Employees
915
Market Cap
9.30B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 958.40M | 778.27M | 432.05% |
| Dec 31, 2024 | 180.13M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | 147.00K | -7.44M | -98.06% |
| Dec 31, 2011 | 7.58M | -7.22M | -48.77% |
| Dec 31, 2010 | 14.80M | -129.44M | -89.74% |
| Dec 31, 2009 | 144.25M | 141.63M | 5,416.06% |
| Dec 31, 2008 | 2.62M | 1.87M | 251.95% |
| Dec 31, 2007 | 743.00K | - | - |
| Dec 31, 2006 | - | - | - |
| Dec 31, 2005 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| BioMarin Pharmaceutical | 3.66B |
| Bio-Techne | 1.22B |
| Caris Life Sciences | 989.61M |
| Corcept Therapeutics | 830.81M |
| TG Therapeutics | 799.54M |
| Krystal Biotech | 470.03M |
| Protagonist Therapeutics | 281.99M |
| Kymera Therapeutics | 102.24M |
MDGL News
- 21 hours ago - Madrigal Pharmaceuticals price target raised to $743 from $709 at Truist - TheFly
- 1 day ago - Madrigal Pharmaceuticals price target raised to $633 from $612 at Canaccord - TheFly
- 1 day ago - H.C. Wainwright questions whistleblower allegations against Madrigal - TheFly
- 1 day ago - Madrigal discloses former employee filed whistleblower complaint - TheFly
- 1 day ago - Madrigal Pharmaceuticals price target raised to $760 from $725 at Citi - TheFly
- 1 day ago - Madrigal Pharmaceuticals Earnings Call Transcript: Q3 2026 - Transcripts
- 1 day ago - Madrigal Pharmaceuticals Earnings release: Q3 2026 - Filings
- 1 day ago - Madrigal Pharmaceuticals Slides: Q3 2026 - Filings